Living Systematic Review: Pharmacological treatments for psoriasis, network meta analysis

The objectives of our review were to compare the efficacy and safety of conventional systemic agents for patients with moderate to severe psoriasis and to provide a ranking of these treatments according to their efficacy and safety by the mean of a network meta-analysis.Our review included 140 studies (31 new studies for the update) and 51,749 participants.  Is it the first iteration of this Living Systematic Review (LSR) or an update?This review was published for the first time in December 2017. This version evolves this review into a LSR. This current version is both an update and first occurrence of the LSR.How often will it be updated? And what will be included in the updates?Search for study, selection, data extraction followed by inclusion of characteristics and risk of bias analysis for each newly identified trial will be performed each month. Every 3 months, each newly identified trial will be incorporated in the Network Meta Analysis.Why is pharmacological treatments for psoriasis a good topic for a LSR?This is a very good topic for LSR as numerous new trials assessing systemic treatments for moderate to severe plaque psoriasis are regularly published. It is demonstrated by the high number of new trials added between the first version published in December 2017 and this one published only two years later and the 42 identified ongoing studies identified in the present study.Who will benefit from this LSR?It is a major resource for guidelines teams who are encouraged ...
Source: Cochrane News and Events - Category: Information Technology Authors: Source Type: news